Who Paid My Doc
Daniel Heller
Physical Medicine & Rehabilitation Warrenton, VA Medical Doctor
NPI 1730397977 CMS profile 260584
52 West Shirley Avenue, Warrenton, VA 20186
General payments
$11,656
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Heller of Warrenton, VA is reported in the CMS Open Payments database as having received $11,656 across 145 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 95th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,147 | 40 | |
| 2024 | General | $3,186 | 44 | |
| 2023 | General | $369 | 23 | |
| 2022 | General | $539 | 10 | |
| 2021 | General | $2,312 | 11 | |
| 2020 | General | $3,061 | 14 | |
| 2019 | General | $41 | 3 |
Beside peers
- Daniel Heller
- Physical Medicine & Rehabilitation median
- Middle half of Physical Medicine & Rehabilitation
- National median
In program year 2025, general payments to Daniel Heller were reported at $2,147. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.
Show as a table
| Year | Daniel Heller | Physical Medicine & Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $41 | $133 | $45–$390 | $163 |
| 2020 | $3,061 | $88 | $29–$272 | $114 |
| 2021 | $2,312 | $116 | $33–$360 | $132 |
| 2022 | $539 | $123 | $40–$378 | $149 |
| 2023 | $369 | $131 | $43–$396 | $160 |
| 2024 | $3,186 | $141 | $45–$409 | $164 |
| 2025 | $2,147 | $139 | $48–$410 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
1,101
Drug cost
$19,372
Branded share of claims
17%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pregabalin | Generic | 168 | $4,829 | |
| Gabapentin | Generic | 186 | $3,608 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 113 | $2,839 | |
| Naloxone Hcl | Generic | 23 | $1,371 | |
| Tizanidine Hcl | Generic | 86 | $1,225 | |
| Etodolac | Generic | 18 | $775 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 56 | $773 | |
| Tramadol Hcl | Generic | 128 | $660 | |
| Morphine Sulfate | Generic | 17 | $645 | |
| Duloxetine Hcl | Generic | 39 | $484 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 74 billing codesPaid by Medicare
$310,564
Medicare patients
458
Services billed
28,998
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 26% | |
| Ischemic heart disease | 24% | |
| Osteoporosis | 21% | |
| Chronic kidney disease | 19% | |
| Depression | 19% | |
| Atrial fibrillation | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 214 | 22,441 | $2,280 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 91 | 261 | $1,436 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 53 | 60 | $446 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 52 | 348 | $250 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 34 | 40 | $200 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 61 | 1,040 | $93 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 22 | 55 | $31 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 58 | 192 | $21 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
145 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Physical Medicine & Rehabilitation in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Physical Medicine & Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.